Year-end Sale % OFF 
Abstract
Objective: SIRT1(silent information regulator 1), a member of the highly conserved sirtuins family, has been reported to be abnormally expressed in a wide variety of cancers. Numerous studies have reported the association between SIRT1 and cancer drug resistance, but the data of different reports remains controversial. To further evaluate the role of SIRT1 in tumor resistance, a meta-analysis based on published studies was conducted. Methods: Relevant articles before September 2018 on SIRT1 and Drug-resistant tumor were searched via PubMed, Embase, Web Of Science (WOS). The studies were chosen for the meta-analysis based on requisite criteria. The relation was analyzed using RevMan 5.3 software. Odds ratios (OR) and their 95% corresponding confidence intervals (CI) were pooled to estimate the effect of specific associations. Results: A total of 14 eligible studies containing 790 patients were included, in which most of the patients overexpressed SIRT1. The results showed that SIRT1 overexpression significantly correlated with the risk of cancer drug resistance (OR=7.99, 95% CI: 5.70–11.21, P<0.00001). Conclusions: The overall data of the shown meta-analysis suggested that the expression of SIRT1 is correlated with cancer risk cancer drug resistance.
Highlights
Certain cancers continue to increase in different parts of the world, and cancers are among the most threat to death.[3]There are surgical treatments, chemotherapy and radiotherapy for tumors
Publications were considered eligible in our quantitative meta-analysis when they met all of the following criteria: (1) The diagnosis of cancers drug resistance was tested by using certain concentrations chemicals to the cancers; (2) Sirtuin 1 (SIRT1) expression was determined by immunohistochemistry(IHC) in the tissues of different cancers; (3) Sufficient information of the correlation of SIRT1 with clinicopathological features or overall survival time was provided to estimate odds ratio (OR) and hazard ratio (HR); (4) Being written as full papers; studies were excluded on the basis of the following criteria: (1) duplicate or overlapping populations; (2) lack of enough statistical data for further quantification analyses; (3) review articles, letters or case reports; (4) All evaluations were independently conducted by two authors to ensure the accuracy of the selection process
SIRT1 is expressed in many cells and was originally identified as a nuclear protein.[21]
Summary
The past few decades have seen significant progress in our understanding of cancer reasons as well as advances in early detection, treatment, and prevention, which have led to declining cancer mortality in the industrialized world.[1, 2] Despite this progress, certain cancers continue to increase in different parts of the world, and cancers are among the most threat to death.[3]There are surgical treatments, chemotherapy and radiotherapy for tumors. Advanced and recurrent cancers are no longer suitable for hand surgery, so drug therapy is necessary to prevent cervical cancer from progress and recurrence. The biggest obstacle to the treatment of recurrent and advanced cancer is tolerance to chemotherapeutic drugs.[4, 5] To overcome the resistance of cancers to drugs, the research of a novel drug resistance mechanism has the uncommonly important scientific meaning and the clinical value. A highly conserved protein family, has been shown to be a significant protease partaking in the cancers drug resistance.[6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
